Immunovant
IMVT
168 hedge funds and large institutions have $1.54B invested in Immunovant in 2025 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 73 increasing their positions, 48 reducing their positions, and 48 closing their positions.
52% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 48
14% more call options, than puts
Call options by funds: $6.75M | Put options by funds: $5.95M
0.52% more ownership
Funds ownership: 55.79% → 56.3% (+0.52%)
5% less capital invested
Capital invested by funds: $1.62B → $1.54B (-$79.9M)
13% less funds holding
Funds holding: 193 → 168 (-25)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
50% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 48
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$38.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$20.5M |
| 3 |
Morgan Stanley
New York
|
+$15.1M |
| 4 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$14.9M |
| 5 |
AC
Armistice Capital
New York
|
+$10.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$19.1M |
| 2 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
-$17.8M |
| 3 |
Principal Financial Group
Des Moines,
Iowa
|
-$13M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$11.4M |
| 5 |
PA
Perceptive Advisors
New York
|
-$10.7M |
IMVT Hedge Fund Activity: Q2 2025 in Review
168 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Immunovant (IMVT) for Q2 2025, worth a combined $1.54B — down 4.9% from $1.62B a quarter earlier.
Sellers outnumbered buyers: 48 funds closed out of IMVT and 24 opened new positions — a net loss of 24 holders — while 48 trimmed existing stakes and 73 added.
The largest buyer was Point72 Asset Management, adding an estimated $38.3M. The largest seller was Viking Global Investors, exiting entirely with an estimated $19.1M sold.
- 168 institutional investors held Immunovant (IMVT) as of Q2 2025, down from 193 in Q1 2025.
- Funds reported $1.54B of Immunovant stock for Q2 2025, down 4.9% quarter-over-quarter.
- 24 funds opened new Immunovant positions in Q2 2025 and 48 closed out, a net change of -24 holders.
- The largest Immunovant buyer in Q2 2025 was Point72 Asset Management, an estimated $38.3M added.
- The largest Immunovant seller in Q2 2025 was Viking Global Investors, an estimated $19.1M sold.
Based on aggregated 13F filings for Q2 2025.